Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System

American Journal of Hematology

Volumn 90, Issue 4, 2015, Pages E66-E72

  Cortes, Jorge ^a   Mauro, Michael ^b   Steegmann, Juan Luis ^c   Saglio, Giuseppe ^d   Malhotra, Rachpal ^e   Ukropec, Jon A ^e   Wallis, Nicola T ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d UNIVERSITY OF TURIN   (Italy)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGE; ANGINA PECTORIS; ARTERY OCCLUSION; ARTICLE; ASCITES; BLEEDING; BONE MARROW NECROSIS; CARDIOVASCULAR DISEASE; CHYLOTHORAX; CONJUNCTIVAL HEMORRHAGE; CORONARY ARTERY OBSTRUCTION; DRUG SAFETY; EDEMA; EFFUSION; FLUID RETENTION; HEART ARRHYTHMIA; HUMAN; HYPERVOLEMIA; INTERMITTENT CLAUDICATION; LUNG DISEASE; LUNG EDEMA; MALIGNANT PLEURA EFFUSION; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; PERICARDIAL EFFUSION; PERIPHERAL ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DISEASE; PERITONEAL FLUID; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QT PROLONGATION; STOMACH ANTRUM VASCULAR ECTASIA; SUBDURAL HEMATOMA; TORSADE DES POINTES; TUMOR BLEEDING; TUMOR NECROSIS; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; FOOD AND DRUG ADMINISTRATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUNG DISEASES; METABOLISM; MIDDLE AGED; POSTMARKETING SURVEILLANCE; STATISTICAL MODEL; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LOGISTIC MODELS; LUNG DISEASES; MIDDLE AGED; PIPERAZINES; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIMIDINES; THIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84925351582     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23938     Document Type: Article

References (57)

1. Sprycel® (dasatinib). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2013.
2. Gleevec® (imatinib mesylate). Full Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013.
3. Tasigna® (nilotinib). Full Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014.
4. Bosulif® (bosutinib). Full Prescribing Information. New York, NY: Pfizer Labs; 2013.
5. Iclusig® (ponatinib). Full Prescribing Information. Cambridge, MA: Ariad Pharmaceuticals, Inc.; 2014.
6. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43:967-968.
7. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33:861-864.
8. Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011;38:218-220.
9. Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30.
10. Philibert L, Cazorla C, Peyrière H, et al. Pulmonary arterial hypertension induced by dasatinib: Positive reintroduction with nilotinib. Fundam Clin Pharmacol 2011;25(Suppl 1):95 (Abstract 476).
11. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-2137.
12. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36:e4-e6.
13. Sano M, Saotome M, Urushida T, et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia-critical alert. Intern Med 2012;51:2337-2340.
14. Kim JC, Shin SH, Yi HG, et al. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib. Herz 2013;38:931-933.
15. Larson RA, Hochhaus A, Saglio G, et al. Cardiac safety profile of imatinib and nilotinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from ENESTnd. Blood 2010;116:Abstract 2291.
16. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-539.
17. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012;12:337-340.
18. Schwarz M, Kim TD, Mirault T, et al. Elevated risk of peripheral artery occlusive disease (PAOD) in nilotinib treated chronic phase chronic myeloid leukemia (CML) patients assessed by ankle-brachial-index (ABI) and duplex ultrasonography. Blood 2012;120:Abstract 914.
19. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-2203.
20. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013;27:1316-1321.
21. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis. Leukemia 2013;27:1310-1315.
22. Levato L, Cantaffa R, Kropp MG, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: A single institution study. Eur J Haematol 2013;90:531-532.
23. Harpaz R, DuMouchel W, LePendu P, et al. Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System. Clin Pharmacol Ther 2013;93:539-546.
24. US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) (formerly AERS) web site. Available at: http://www.fda.gov/cder/aers/default.htm. Accessed 10 April 2014.
25. US Food and Drug Administration. What is a serious adverse event? Available at: http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm. Accessed 10 April 2014.
26. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am Statistician 1999:53:177-190.
27. MedDRA Maintenance and Support Services Organization. Introductory Guide to MedDRA Version 15.0. Publication no. MSSO-DI-6003-15.0.0. Chantilly, VA: International Federation of Pharmaceutical Manufacturers and Associations; 2012.
28. Pearson RK, Hauben M, Goldsmith DI, et al. Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform 2009;78:e97-e103.
29. MedDRA Maintenance and Support Services Organization. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 15.0. Publication no. MSSO-DI-6226-15.0.0. Chantilly, VA: International Federation of Pharmaceutical Manufacturers and Associations; 2012.
30. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002;25:381-392.
31. Deshpande G, Gogolak V, Weiss-Smith S. Data mining in drug safety: Review of published threshold criteria for defining signals of disproportionate reporting. Pharmaceut Med 2010;24:37-43.
32. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance-Lack of vigilance, lack of trust. JAMA 2004;292:2647-2650.
33. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004;24:743-749.
34. Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias. Drug Saf 2007;30:891-898.
35. Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: Proceed with caution. Pharmacoepidemiol Drug Saf 2007;16:359-365.
36. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009;18:427-436.
37. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 2013;10:796-803.
38. Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA drug safety surveillance program: Adverse event reporting trends. Arch Intern Med 2011;171:591-593.
39. Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: Gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2013;50:569-577.
40. Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: The example of sertindole. Pharmacoepidemiol Drug Saf 2003;12:271-281.
41. Hauben M, Reich L, Gerrits CM. Reports of hyperkalemia after publication of RALES-A pharmacovigilance study. Pharmacoepidemiol Drug Saf 2006;15:775-783.
42. Quintás-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914.
43. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-386.
44. Tamura T, Tasaka T, Fujimoto M, et al. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Haematologica 2004;89:e109-e110.
45. Matsue K, Takeuchi M, Koseki M, Uryu H. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol 2006;85:542-544.
46. Campiotti L, Codari R, Appio L, et al. Bone marrow necrosis related to imatinib mesylate therapy for CML bilineal blast crisis. Leuk Res 2007;31:1768-1770.
47. Vanel D, Bonvalot S, Le Pechoux C, et al. Imatinib-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases. Skeletal Radiol 2007;36:895-898.
48. Aras Y, Akcakaya MO, Unal SN, Bilgic B, Unal OF. Bone marrow necrosis secondary to imatinib usage, mimicking spinal metastasis on magnetic resonance imaging and FDG-PET/CT. J Neurosurg Spine 2012;16:57-60.
49. Burton C, Azzi A, Kerridge I. Adverse events after imatinib mesylate therapy. N Engl J Med 2002;346:712-713.
50. Sprycel® (dasatinib). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
51. Groeneveldt JA, Gans SJM, Bogaard HJ, Vonk-Noordegraaf A. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J 2013;42:869-870.
52. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-1177.
53. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 2013;127:1128-1138.
54. Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011;103:1347-1348.
55. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011;86:610-611.
56. Tasigna® (nilotinib). Full Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
57. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916.